ICER to Assess Treatment for Schizophrenia
July 07, 2023
July 07, 2023
BOSTON, Massachusetts, July 7 (TNSres) -- The Institute for Clinical and Economic Review issued the following news release on July 5, 2023:
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of xanomeline tartrate/trospium chloride (KarXT, Karuna Therapeutics) for the treatment of schizophrenia.
The assessment will be publicly discussed during a meeting of the New England CEPAC (New . . .
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of xanomeline tartrate/trospium chloride (KarXT, Karuna Therapeutics) for the treatment of schizophrenia.
The assessment will be publicly discussed during a meeting of the New England CEPAC (New . . .